SDZXF Stock Chart & Stats
$83.94
$5.32(6.94%)
At close: 4:00 PM EDT
$83.94
$5.32(6.94%)
Day’s Range― - ―
52-Week Range$55.50 - $94.55
Previous CloseN/A
Volume112.00
Average Volume (3M)57.00
Market Cap
$35.70B
Enterprise Value$36.05K
Total Cash (Recent Filing)$1.25B
Total Debt (Recent Filing)$6.22B
Price to Earnings (P/E)53.2
Beta0.76
Next Earnings
Feb 17, 2027EPS Estimate
2.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.51
Shares Outstanding440,000,000
10 Day Avg. Volume70
30 Day Avg. Volume57
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.35
Price to Sales (P/S)2.82
P/FCF Ratio38.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$98.29Price Target Upside17.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)4.99
Revenue Forecast (FY)$14.82B
Bulls Say, Bears Say
Bulls Say
Revenue & Profit ReboundA ~25% revenue increase and net margin recovery to ~8% in 2025 reflects a meaningful operational turnaround versus prior years. This durable improvement indicates restored pricing, volume or product mix dynamics and supports sustained cash generation and return-on-equity if management maintains execution.
Gross Margin ResilienceConsistently strong gross margins (~46–48%) point to durable product economics across Sandoz's generics and biosimilars portfolio. Stable manufacturing and supply economics underpin margins even when selling prices fluctuate, providing a buffer for operating margins and long-term profitability resilience.
New Brazil Semaglutide ApprovalRegulatory approval and a Brazil commercial partnership for a semaglutide product gives Sandoz exposure to a higher‑value diabetic therapy market (~$1.8B). This diversifies mix beyond low‑margin generics and is a structural growth lever if commercial execution and uptake meet expectations over the medium term.
Bears Say
Earnings & FCF VolatilityWide swings in free cash flow across years indicate sensitivity to working capital, product timing and investment cycles. Such volatility complicates capital allocation, makes forecasting harder, and raises execution risk for sustaining investments in manufacturing, R&D or commercial launch programs.
Rising Absolute DebtAn increase in absolute debt levels from 2023–2025 reduces financial flexibility even though leverage ratios remain moderate. Higher debt raises interest and refinancing risk, constrains strategic choices (M&A, capex), and can amplify earnings sensitivity in slower sales periods.
Structural Pricing PressureSandoz's core generics model depends on high volumes in price‑competitive markets where payers and reference pricing limit price upside. This structural pressure caps margin expansion, makes returns cyclical, and forces constant cost and scale discipline to protect profitability over the medium term.
Sandoz Group Ltd News
SDZXF FAQ
What was Sandoz Group Ltd’s price range in the past 12 months?
Sandoz Group Ltd lowest stock price was $55.50 and its highest was $94.55 in the past 12 months.
What is Sandoz Group Ltd’s market cap?
Sandoz Group Ltd’s market cap is $35.70B.
When is Sandoz Group Ltd’s upcoming earnings report date?
Sandoz Group Ltd’s upcoming earnings report date is Feb 17, 2027 which is in 154 days.
How were Sandoz Group Ltd’s earnings last quarter?
Sandoz Group Ltd released its earnings results on Aug 05, 2026. The company reported $1.71 earnings per share for the quarter, missing the consensus estimate of $1.79 by -$0.08.
Is Sandoz Group Ltd overvalued?
According to Wall Street analysts Sandoz Group Ltd’s price is currently Undervalued.
Does Sandoz Group Ltd pay dividends?
Sandoz Group Ltd does not currently pay dividends.
What is Sandoz Group Ltd’s EPS estimate?
Sandoz Group Ltd’s EPS estimate is 2.26.
How many shares outstanding does Sandoz Group Ltd have?
Sandoz Group Ltd has 440,000,000 shares outstanding.
What happened to Sandoz Group Ltd’s price movement after its last earnings report?
Sandoz Group Ltd reported an EPS of $1.71 in its last earnings report, missing expectations of $1.79. Following the earnings report the stock price went up 5.83%.
Which hedge fund is a major shareholder of Sandoz Group Ltd?
Currently, no hedge funds are holding shares in SDZXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sandoz Group Ltd
Operating globally, Sandoz Group AG specializes in the development, production, and distribution of generic medications and biosimilar products. The company's portfolio includes the creation and sale of finished dosage forms for small molecule pharmaceuticals, often supplied to other entities. Sandoz is also a significant player in the biotechnology sector, providing protein-based products such as biosimilars and offering specialized manufacturing services within this field. Furthermore, it supplies anti-infective products, including active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. Established in 1886, Sandoz maintains its headquarters in Rotkreuz, Switzerland.
SDZXF Company Deck
SDZXF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong sales growth, particularly in the biosimilars segment and North American market recovery. However, the financial performance was impacted by negative free cash flow, a decline in core EBITDA margin, significant restructuring, and legal costs.View all SDZXF earnings summariesSDZXF Stock 12 Month Forecast
Average Price Target
$98.29
▲(17.10% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
PolyPeptide Group AG
―
Galenica AG
―
Ownership Overview
―
Insiders
8.70% Mutual Funds
<0.01% Other Institutional Investors
77.48% Public Companies and
Individual Investors